93,000 patients studied: what decades of data reveal about carcinoid cancer survival
NCT ID NCT07317713
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at nearly 94,000 people diagnosed with gastrointestinal carcinoid tumors between 2000 and 2022. Researchers used a large cancer database to calculate how many patients died from their tumor compared to the general population. The goal was to fill gaps in knowledge about long-term survival for these rare, slow-growing cancers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this research could help doctors better predict survival and tailor follow-up for people with gastrointestinal carcinoid tumors.
What could go wrong
This is an observational study using existing data, not a treatment trial. It cannot prove what causes better or worse outcomes, only highlight patterns.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.